Comparative Pharmacology
Head-to-head clinical analysis: FOLOTYN versus TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOLOTYN versus TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE.
FOLOTYN vs TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FOLOTYN (pralatrexate) is a folate analogue metabolic inhibitor that competes for the reduced folate carrier and folylpolyglutamate synthetase, leading to intracellular accumulation of polyglutamated metabolites that inhibit dihydrofolate reductase (DHFR) and thymidylate synthase, thereby disrupting DNA synthesis and cell proliferation.
Trifluridine is a thymidine-based nucleoside analog that incorporates into DNA, interfering with DNA synthesis and function. Tipiracil hydrochloride inhibits thymidine phosphorylase, preventing trifluridine degradation and increasing its systemic exposure.
3.0 mg/m2 intravenously over 3-5 minutes on days 1, 8, and 15 of a 28-day cycle.
35 mg/m² orally twice daily on days 1-5 and 8-12 of each 28-day cycle. Maximum dose: 80 mg per dose.
None Documented
None Documented
Terminal elimination half-life is approximately 4–6 hours; clinical context: supports weekly dosing schedule.
The terminal elimination half-life of trifluridine is approximately 1.4 to 2.1 hours. For tipiracil, the half-life is about 2.1 to 3.3 hours. The short half-lives necessitate twice-daily dosing to maintain therapeutic concentrations.
Primarily renal excretion (approximately 80% of the dose recovered in urine over 24 hours, with about 60% as unchanged drug); biliary/fecal elimination accounts for <1%.
Trifluridine is primarily eliminated via metabolism and renal excretion. Approximately 29% of the trifluride dose is recovered in urine as trifluridine and its metabolites, with less than 3% as unchanged drug. Fecal excretion accounts for about 38% of the dose, mainly as metabolites. Tipiracil is predominantly excreted renally (about 55% as unchanged drug and metabolites) and fecally (about 19%).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent